Short answer
Editas Medicine, Inc. (EDIT) filed an 8-K current report with the SEC on May 26, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events). $125.0M gross equity offering: 55,555,556 shares plus warrants, priced at $2.25 per share-warrant unit.
Editas Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $125.0M gross equity offering: 55,555,556 shares plus warrants, priced at $2.25 per share-warrant unit
- Approximately $117.0M net proceeds, strengthening funding for Editas’ operations and clinical development
- Warrants cover 55,555,556 shares at $3.50 exercise price, potentially adding approximately $192.5M cash
- Immediate warrant exercise creates substantial future dilution, with expiration tied to EDIT-401 Phase 1 data or three years
- Closing expected May 27, 2026, subject to customary conditions
Item 8.01 · Other Events
- Underwritten public offering priced May 26, 2026, providing financing for Editas Medicine’s operations
- Net offering proceeds plus cash at March 31, 2026 expected to fund operations into the second half of 2028
- Extended runway may reduce near-term financing risk and support ongoing clinical programs
- Runway estimate depends on operating forecasts, offering closing conditions, market conditions, and future capital needs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Editas Medicine, Inc. 8-K filings
Get the next EDIT 8-K as it lands
Follow EDIT for push alerts, or ask the research agent what this filing means.